8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 29, 2024

Revvity, Inc.

(Exact Name of Registrant as Specified in its Charter)

Massachusetts	001-05075	04-2052042
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File Number)	(IRS Employer Identification No.)

940 Winter Street	Waltham	Massachusetts	02451
(Address of Principal Executive Offices)			(Zip Code)

Registrant’s telephone number, including area code: (781) 663-6900

Not applicable.

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, $1 par value per share	RVTY	The New York Stock Exchange
1.875% Notes due 2026	RVTY 26	The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 2.02. Results of Operations and Financial Condition

    On April 29, 2024, Revvity, Inc. announced its financial results for the first quarter ended March 31, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits

(d)    Exhibits

                        EXHIBIT INDEX

Exhibit No.		Description
	99.1*	Press Release entitled “Revvity Announces Financial Results for the First Quarter of 2024”, issued by Revvity, Inc. on April 29, 2024.
	104	Cover Page Interactive Data File (embedded within the Inline XBRL)

* This exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	REVVITY, INC.
Date: April 29, 2024	By: /s/ Maxwell Krakowiak Maxwell Krakowiak Senior Vice President and Chief Financial Officer

EX-99.1

FOR IMMEDIATE RELEASE

April 29, 2024

Revvity Announces Financial Results for the First Quarter of 2024

•Revenue of $650 million; (4)% reported growth; (3)% organic growth

•First quarter GAAP EPS of $0.21; Adjusted EPS from continuing operations of $0.98

•Reaffirms full year 2024 organic growth and adjusted EPS guidance

WALTHAM, Mass. -- Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended March 31, 2024.

The Company reported GAAP earnings per share of $0.21, as compared to $4.50 in the same period a year ago. GAAP revenue for the quarter was $650 million, as compared to $675 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $44 million, as compared to $76million for the same period a year ago. GAAP operating profit margin from continuing operations was 6.8% as a percentage of revenue, as compared to 11.3% in the same period a year ago.

Adjusted earnings per share from continuing operations for the quarter was $0.98, as compared to $1.01 in the same period a year ago. Adjusted revenue for the quarter was $650 million, as compared to $675 million in the same period a year ago. Adjusted operating income was $166 million, as compared to $189 million for the same period a year ago. Adjusted operating profit margin was 25.5% as a percentage of adjusted revenue, as compared to 28.0% in the same period a year ago.

Adjustments for the Company's non-GAAP financial measures have been noted in the attached reconciliations.

"It was great to see the significant progress we achieved on our strategic priorities during the first few months of the year," said Prahlad Singh, president and chief executive officer of Revvity. "We were able to bring a number of cutting-edge innovations to market while continuing to make meaningful traction on optimizing the business as we work through this period of industry adjustment. The improvements we have made position us extremely well to deliver differentiated performance in the years to come."

Financial Overview by Reporting Segment

Life Sciences

•First quarter 2024 revenue was $303 million, as compared to $328 million in the same period a year ago. Reported revenue decreased 8% and organic revenue decreased 8% as compared to the same period a year ago.

•First quarter 2024 adjusted operating income was $102 million, as compared to $129 million in the same period a year ago. Adjusted operating profit margin was 33.6% as a percentage of adjusted revenue, as compared to 39.4% in the same period a year ago.

Diagnostics

•First quarter 2024 revenue was $347 million, as compared to $347 million in the same period a year ago. Reported revenue was flat and organic revenue increased 1% as compared to the same period a year ago.

•First quarter 2024 adjusted operating income was $75 million, as compared to $74 million in the same period a year ago. Adjusted operating profit margin was 21.7% as a percentage of adjusted revenue, as compared to 21.5% in the same period a year ago.

Full Year 2024 Guidance

For the full year 2024, the Company is updating its full year 2024 total revenue guidance to a range of $2.76-$2.82 billion to reflect recent changes in foreign currency exchange rates. The Company is also reaffirming its adjusted EPS guidance of $4.55-$4.75 and organic growth guidance of 1-3%.

Adjusted EPS guidance for the full year 2024 is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The timing and amounts of such events and items could be material to the Company’s results prepared in accordance with GAAP.

Webcast Information

The Company will discuss its first quarter 2024 results and its outlook for business trends during a webcast on April 29, 2024, at 8:00 a.m. Eastern Time. A live audio webcast and presentation will be available on the Investors section of the Company’s website, ir.revvity.com.

Use of Non-GAAP Financial Measures

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are included below following our GAAP financial statements.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "estimates," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and divestitures, license technologies, or to successfully integrate acquired businesses or licensed technologies into our existing businesses or to make them profitable; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (8) disruptions in the supply of raw materials and supplies; (9) our ability to retain key personnel; (10) significant disruption in our information technology systems, or cybercrime; (11) our ability to realize the full value of our intangible assets; (12) our failure to adequately protect our intellectual property; (13) the loss of any of our licenses

or licensed rights; (14) the manufacture and sale of products exposing us to product liability claims; (15) our failure to maintain compliance with applicable government regulations; (16) our failure to comply with data privacy and information security laws and regulations; (17) regulatory changes; (18) our failure to comply with healthcare industry regulations; (19) economic, political and other risks associated with foreign operations; (20) our ability to obtain future financing; (21) restrictions in our credit agreements; (22) significant fluctuations in our stock price; (23) reduction or elimination of dividends on our common stock; and (24) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

Revvity, Inc. and Subsidiaries

CONDENSED CONSOLIDATED INCOME STATEMENTS

	Three Months Ended
(In thousands, except per share data)	March 31, 2024		April 2, 2023
Revenue	$	649,920	$	674,865
Cost of revenue	294,873		293,499
Selling, general and administrative expenses	260,571		248,557
Research and development expenses	50,360		56,690
Operating income from continuing operations	44,116		76,119
Interest income	(20,086)		(5,272)
Interest expense	24,397		22,738
Change in fair value of financial securities	806		(2,768)
Other expense, net	4,450		31,981
Income from continuing operations, before income taxes	34,549		29,440
Provision for income taxes	5,853		4,595
Income from continuing operations	28,696		24,845
(Loss) income from discontinued operations	(2,683)		544,630
Net income	$	26,013	$	569,475
Diluted earnings per share:
Income from continuing operations	$	0.23	$	0.20
(Loss) income from discontinued operations	(0.02)		4.31
Net income	$	0.21	$	4.50
Weighted average diluted shares of common stock outstanding	123,538		126,469
ABOVE PREPARED IN ACCORDANCE WITH GAAP

Additional supplemental information (1):
(per share, continuing operations)
GAAP EPS from continuing operations	$	0.23	$	0.20
Amortization of intangible assets	0.74		0.73
Debt extinguishment income	—		(0.03)
Purchase accounting adjustments	0.05		(0.01)
Acquisition and divestiture-related costs	0.08		0.35
Change in fair value of financial securities	0.01		(0.02)
Significant environmental matters	—		0.01
Restructuring and other, net	0.10		0.02
Tax on above items	(0.23)		(0.23)
Significant tax items	—		(0.01)
Adjusted EPS from continuing operations	$	0.98	$	1.01
(1) amounts may not sum due to rounding

Revvity, Inc. and Subsidiaries

REVENUE AND OPERATING INCOME (LOSS)

	Three Months Ended
(In thousands, except percentages)	March 31, 2024			April 2, 2023
Adjusted revenue and operating income
Reported revenue	$	649,920		$	674,865
Revenue purchase accounting adjustments	209			206
Adjusted revenue	$	650,129		$	675,071
Reported operating income from continuing operations	$	44,116		$	76,119
OP%	6.8		%	11.3		%
Amortization of intangible assets	91,238			91,811
Purchase accounting adjustments	6,622			(914)
Acquisition and divestiture-related costs	11,462			17,951
Significant environmental matters	—			1,132
Restructuring and other, net	12,356			3,095
Adjusted operating income	$	165,794		$	189,194
OP%	25.5		%	28.0		%
Segment revenue and segment operating income
Life Sciences	$	303,037		$	328,441
Diagnostics	347,092			346,630
Revenue purchase accounting adjustments	(209)			(206)
Reported revenue	$	649,920		$	674,865
Life Sciences	$	101,725		$	129,459
	33.6		%	39.4		%
Diagnostics	75,430			74,432
	21.7		%	21.5		%
Corporate	(11,361)			(14,697)
Subtotal reportable segments operating income	165,794			189,194
Amortization of intangible assets	(91,238)			(91,811)
Purchase accounting adjustments	(6,622)			914
Acquisition and divestiture-related costs	(11,462)			(17,951)
Significant environmental matters	—			(1,132)
Restructuring and other, net	(12,356)			(3,095)
Reported operating income from continuing operations	$	44,116		$	76,119
REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP

Revvity, Inc. and Subsidiaries

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)	March 31, 2024		December 31, 2023
Current assets:
Cash and cash equivalents	$	998,081	$	913,163
Marketable securities	697,327		689,916
Accounts receivable, net	588,974		632,811
Inventories, net	414,029		428,062
Other current assets	360,929		337,139
Total current assets	3,059,340		3,001,091
Property, plant and equipment, net	503,964		509,654
Operating lease right-of-use assets, net	148,724		155,083
Intangible assets, net	2,919,145		3,022,321
Goodwill	6,503,897		6,533,550
Other assets, net	297,635		342,966
Total assets	$	13,432,705	$	13,564,665
Current liabilities:
Current portion of long-term debt	$	711,443	$	721,872
Accounts payable	183,532		204,121
Accrued expenses and other current liabilities	479,247		524,470
Total current liabilities	1,374,222		1,450,463
Long-term debt	3,164,994		3,177,770
Long-term liabilities	919,795		930,946
Operating lease liabilities	127,198		132,747
Total liabilities	5,586,209		5,691,926
Total stockholders' equity	7,846,496		7,872,739
Total liabilities and stockholders' equity	$	13,432,705	$	13,564,665
PREPARED IN ACCORDANCE WITH GAAP

Revvity, Inc. and Subsidiaries

CONSOLIDATED STATEMENTS OF CASH FLOWS

	Three Months Ended
	March 31, 2024		April 2, 2023
	(In thousands)
Operating activities:
Net income	$	26,013	$	569,475
Loss (income) from discontinued operations, net of income taxes	2,683		(544,630)
Income from continuing operations	28,696		24,845
Adjustments to reconcile income from continuing operations
to net cash provided by (used in) continuing operations:
Stock-based compensation	11,692		9,893
Restructuring and other, net	12,356		3,096
Depreciation and amortization	107,802		109,008
Change in fair value of contingent consideration	6,173		(1,360)
Amortization of deferred debt financing costs and accretion of discounts	1,736		1,792
Change in fair value of financial securities	806		(2,768)
Debt extinguishment gain	—		(3,345)
Unrealized foreign exchange (gain) loss	(377)		26,095
Changes in assets and liabilities which provided (used) cash, excluding
effects from companies acquired:
Accounts receivable, net	37,189		34,424
Inventories	7,209		(18,520)
Accounts payable	(18,227)		(4,895)
Accrued expenses and other	(44,909)		(106,591)
Net cash provided by operating activities of continuing operations	150,146		71,674
Net cash used in operating activities of discontinued operations	(2,583)		(8,211)
Net cash provided by operating activities	147,563		63,463
Investing activities:
Capital expenditures	(17,844)		(20,946)
Purchases of US Treasury Securities	—		(193,454)
Purchases of notes receivables	(337)		—
Cash paid for acquisitions, net of cash, cash equivalents and restricted cash acquired	—		(686)
Net cash used in investing activities of continuing operations	(18,181)		(215,086)
Net cash provided by investing activities of discontinued operations	—		2,079,588
Net cash (used in) provided by investing activities	(18,181)		1,864,502
Financing Activities:
Payment of debt issuance costs	—		(49,603)
Net (payments) proceeds on other credit facilities	(10,811)		7,867
Payments for acquisition-related contingent consideration	(8,749)		(1,475)
Proceeds from issuance of common stock under stock plans	3,943		523
Purchases of common stock	(10,756)		(61,656)
Dividends paid	(8,640)		(8,841)
Net cash used in financing activities of continuing operations	(35,013)		(113,185)

Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(9,277)		(16,969)
Net increase in cash, cash equivalents, and restricted cash	85,092		1,797,811
Cash, cash equivalents, and restricted cash at beginning of period	914,373		470,746
Cash, cash equivalents, and restricted cash at end of period	$	999,465	$	2,268,557
Supplemental disclosure of cash flow information:
Reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total shown in the consolidated statements of cash flows:
Cash and cash equivalents	$	998,081	$	2,267,183
Restricted cash included in other current assets	1,384		1,019
Restricted cash included in other assets	—		355
Total cash, cash equivalents and restricted cash	$	999,465	$	2,268,557
PREPARED IN ACCORDANCE WITH GAAP

Revvity, Inc. and Subsidiaries

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)

	Continuing Operations
	Three Months Ended
	March 31, 2024
Organic revenue growth:
Reported revenue growth from continuing operations	-4%
Less: effect of foreign exchange rates	0%
Less: effect of acquisitions including purchase accounting adjustments           and impact of divested businesses	0%
Organic revenue growth from continuing operations	-3%
	Life Sciences
	Three Months Ended
	March 31, 2024
Organic revenue growth:
Reported revenue growth from continuing operations	-8%
Less: effect of foreign exchange rates	0%
Less: effect of acquisitions including purchase accounting adjustments           and impact of divested businesses	0%
Organic revenue growth from continuing operations	-8%
	Diagnostics
	Three Months Ended
	March 31, 2024
Organic revenue growth:
Reported revenue growth from continuing operations	0%
Less: effect of foreign exchange rates	-1%
Less: effect of acquisitions including purchase accounting adjustments           and impact of divested businesses	0%
Organic revenue growth from continuing operations	1%
	Continuing Operations
	projected
	Twelve Months Ended
	December 29, 2024
Organic revenue growth:
Reported revenue growth from continuing operations	0% - 3%
Less: effect of foreign exchange rates	0%
Less: effect of acquisitions including purchase accounting adjustments           and impact of divested businesses	0%
Organic revenue growth from continuing operations	1% - 3%
(1) amounts may not sum due to rounding

Explanation of Non-GAAP Financial Measures

We report our financial results in accordance with GAAP. However, management believes that, in order to more fully understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash, non-recurring or other items, which result from facts and circumstances that vary in frequency and impact on continuing operations. Accordingly, we present non-GAAP financial measures as a supplement to the financial measures we present in accordance with GAAP. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by adjusting for certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management's ability to make useful forecasts. Management believes these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.

We use the term “adjusted revenue” to refer to GAAP revenue, including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term “adjusted revenue growth” to refer to the measure of comparing current period adjusted revenue with the corresponding period of the prior year.

We use the term “organic revenue” to refer to GAAP revenue, excluding the effect of foreign currency changes and revenue from recent acquisitions and divestitures and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term “organic revenue growth” to refer to the measure of comparing current period organic revenue with the corresponding period of the prior year.

We use the term “adjusted gross margin” to refer to GAAP gross margin, excluding amortization of intangible assets and inventory fair value adjustments related to business acquisitions, asset impairments, and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to business combination accounting rules. We use the related term “adjusted gross margin percentage” to refer to adjusted gross margin as a percentage of adjusted revenue.

We use the term “adjusted SG&A expense” to refer to GAAP SG&A expense, excluding amortization of intangible assets, purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, asset impairments, significant environmental charges, and restructuring and other charges. We use the related term “adjusted SG&A percentage” to refer to adjusted SG&A expense as a percentage of adjusted revenue.

We use the term “adjusted R&D expense” to refer to GAAP R&D expense, excluding amortization of intangible assets and purchase accounting adjustments. We use the related term “adjusted R&D percentage” to refer to adjusted R&D expense as a percentage of adjusted revenue.

We use the term “adjusted net interest and other expense” to refer to GAAP net interest and other expense, excluding adjustments for mark-to-market accounting on post-retirement benefits, changes in foreign exchange and interest associated with acquisitions and divestitures, changes in the value of financial securities and debt extinguishment costs.

We use the term “adjusted operating income” to refer to GAAP operating income, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding amortization of intangible assets, other purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, significant environmental charges, asset impairments, and restructuring and other charges. We use the related terms “adjusted operating profit percentage,” “adjusted operating profit margin,” or “adjusted operating margin” to refer to adjusted operating income as a percentage of adjusted revenue.

We use the term “adjusted earnings per share,” or “adjusted EPS,” to refer to GAAP earnings per share, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding discontinued operations, amortization of intangible assets, debt extinguishment costs, other purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, significant environmental charges, changes in the value of financial securities, disposition of businesses and assets, net, changes in foreign exchange and interest associated with acquisitions and divestitures, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.

We use the term “adjusted earnings per share from continuing operations” to refer to GAAP earnings per share from continuing operations, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, amortization of intangible assets, debt extinguishment costs, other purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, significant environmental charges, changes in the value of financial securities, disposition of businesses and assets, net, changes in foreign exchange and interest associated with acquisitions and divestitures, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.

Management includes or excludes the effect of each of the items identified below in the applicable non-GAAP financial measure referenced above for the reasons set forth below with respect to that item:

lAmortization of intangible assets—purchased intangible assets are amortized over their estimated useful lives and generally cannot be changed or influenced by management after the acquisition. Accordingly, this item is not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.

lDebt extinguishment costs—we incur costs and income related to the extinguishment of debt; including make-whole payments to debt holders, accelerated amortization of debt fees and discounts, and expense or income from hedges to lock in make-whole payments. We exclude the impact of these items from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations.  

lRevenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules—accounting rules require us to account for the fair value of revenue from contracts assumed in connection with our acquisitions. As a result, our GAAP results reflect the fair value of those revenues, which is not the same as the revenue that otherwise would have been recorded by the acquired entity. We include such revenue in our non-GAAP measures because we believe the fair

value of such revenue does not accurately reflect the performance of our ongoing operations for the period in which such revenue is recorded.

lOther purchase accounting adjustments—accounting rules require us to adjust various balance sheet accounts, including inventory, fixed assets and deferred rent balances to fair value at the time of the acquisition. As a result, the expenses for these items in our GAAP results are not the same as what would have been recorded by the acquired entity. Accounting rules also require us to estimate the fair value of contingent consideration at the time of the acquisition, and any subsequent changes to the estimate or payment of the contingent consideration and purchase accounting adjustments are charged to expense or income. We exclude the impact of any changes to contingent consideration from our non-GAAP measures because we believe these expenses or benefits do not accurately reflect the performance of our ongoing operations for the period in which such expenses or benefits are recorded.

lAcquisition and divestiture-related expenses—we incur legal, due diligence, stay bonuses, incentive awards, stock-based compensation, interest, foreign exchange gains and losses, integration expenses, rebranding expenses, and other costs related to acquisitions and divestitures. We exclude these expenses from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations.

lAsset impairments—we incur expense related to asset impairments. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.

lRestructuring and other charges—restructuring and other charges consist of employee severance, other exit costs as well as the cost of terminating certain lease agreements or contracts as well as costs associated with relocating facilities. Management does not believe such costs accurately reflect the performance of our ongoing operations for the period in which such costs are reported.

lAdjustments for mark-to-market accounting on post-retirement benefits—we exclude adjustments for mark-to-market accounting on post-retirement benefits, and therefore only our projected costs are used to calculate our non-GAAP measures. We exclude these adjustments because they do not represent what we believe our investors consider to be costs of producing our products, investments in technology and production, and costs to support our internal operating structure.

lSignificant litigation matters and settlements—we incur expenses related to significant litigation matters, including the costs to settle or resolve various claims and legal proceedings. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.

lSignificant environmental charges—we incur expenses related to significant environmental charges. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.

lDisposition of businesses and assets, net—we exclude the impact of gains or losses from the disposition of businesses and assets from our adjusted earnings per share. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported.

lImpact of foreign currency changes on the current period—we exclude the impact of foreign currency associated with acquisitions and divestitures from these measures by using the prior

period’s foreign currency exchange rates for the current period because foreign currency exchange rates are subject to volatility and can obscure underlying trends.

lImpact of significant tax events—we exclude the impact of significant tax events. Management does not believe the impact of significant tax events accurately reflects the performance of our ongoing operations for the periods in which the impact of such events was recorded.

lChanges in value of financial securities—we exclude the impact of changes in the value of financial securities. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported.

# # #

The tax effect for discontinued operations is calculated based on the authoritative guidance in the Financial Accounting Standards Board’s Accounting Standards Codification 740, Income Taxes. The tax effect for amortization of intangible assets, inventory fair value adjustments related to business acquisitions, changes to the fair values assigned to contingent consideration, debt extinguishment costs, other costs related to business acquisitions and divestitures, significant litigation matters and settlements, significant environmental charges, changes in the fair value of financial securities, adjustments for mark-to-market accounting on post-retirement benefits, disposition of businesses and assets, net, restructuring and other charges, and the revenue from contracts acquired with various acquisitions is calculated based on operational results and applicable jurisdictional law, which contemplates tax rates currently in effect to determine our tax provision. The tax effect for the impact from foreign currency exchange rates on the current period is calculated based on the average rate currently in effect to determine our tax provision.

The non-GAAP financial measures described above are not meant to be considered superior to, or a substitute for, our financial statements prepared in accordance with GAAP. There are material limitations associated with non-GAAP financial measures because they exclude charges that have an effect on our reported results and, therefore, should not be relied upon as the sole financial measures by which to evaluate our financial results. Management compensates and believes that investors should compensate for these limitations by viewing the non-GAAP financial measures in conjunction with the GAAP financial measures. In addition, the non-GAAP financial measures included in this earnings announcement may be different from, and therefore may not be comparable to, similar measures used by other companies.

Each of the non-GAAP financial measures listed above is also used by our management to evaluate our operating performance, communicate our financial results to our Board of Directors, benchmark our results against our historical performance and the performance of our peers, evaluate investment opportunities including acquisitions and discontinued operations, and determine the bonus payments for senior management and employees.

Contacts:

Investor Relations:                        Media Contact:                    
Steve Willoughby                        Fara Goldberg (781) 663-5699

steve.willougby@revvity.comfara.goldberg@revvity.com

XML

Cover	Apr. 29, 2024
Cover [Abstract]
Document Type	8-K
Document Information [Line Items]
Entity Registrant Name	Revvity, Inc.
Document Period End Date	Apr. 29, 2024
Entity Incorporation, State or Country Code	MA
Entity File Number	001-05075
Entity Tax Identification Number	04-2052042
Entity Address, Address Line One	940 Winter Street
Entity Address, City or Town	Waltham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02451
City Area Code	781
Local Phone Number	663-6900
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Entity Central Index Key	0000031791
Amendment Flag	false
Common Stock
Document Information [Line Items]
Title of 12(b) Security	Common stock, $1 par value per share
Trading Symbol	RVTY
Security Exchange Name	NYSE
One875NotesDue2026Member
Document Information [Line Items]
Title of 12(b) Security	1.875% Notes due 2026
Trading Symbol	RVTY 26
Security Exchange Name	NYSE